@FierceBiotech: Novo's liraglutide works in diabetes and obesity. How about NASH? Story | Follow @FierceBiotech
@JohnCFierce: $EBIO down 78%--That's what you call an extinction level event. ELEven | Follow @JohnCFierce
> Mark Fitzpatrick, who resigned as CFO from Aegerion Pharmaceuticals ($AEGR) last week, has taken the same position at Chiasma. More
> Baxter ($BAX) is still on target to spin off its biopharma business by mid-year, the company said, expecting the new company, Baxalta, to post between 6% and 8% sales growth in its first year of independence. News
> Endo ($ENDP) has agreed to acquire Par Pharmaceutical for $8 billion. Story
Medical Device News
@FierceMedDev: ICYMI: Study: Remote monitoring of cardiac device patients results in better survival, less hospitalization. Article | Follow @FierceMedDev
@VarunSaxena2: The FierceBiotech panel: Top research execs tackle the fast-changing field of cancer drug R&D. Editor's corner | Follow @VarunSaxena2
@EmilyWFierce: Endo scoops up Par Pharma for $8B to gain ground in injectables. FiercePharma story | Follow @EmilyWFierce
> Tech industry group IEEE releases software security guidelines for medical devices. More
> Apollo's minimally invasive intragastric weight-loss balloon shows promise in clinical trial. Article
Pharma News
@FiercePharma: Who are the top 10 advertisers in Big Pharma? Find out here. FiercePharmaMarketing feature | Follow @FiercePharma
@CarlyHFierce: No Namenda hard switch? No problem, Actavis execs say, with Namzaric on the horizon. More from FiercePharmaMarketing | Follow @CarlyHFierce
> AstraZeneca, betting on biologics, will build a $285M facility in Sweden. Report
> Endo scoops up Par Pharma for $8B to gain ground in injectables. Article
Pharma Marketing News
> Diabetes app 'One Drop' drops with digerati backing. Article
> AZ bets big on biologics with $285M Swedish facility. Item
> Sanofi seeks the next Teenage Idol in meningitis vaccine campaign. More
> Can pharma + tech wearables be a match made in patient heaven? Story
> No Namenda hard switch? No problem, Actavis execs say, with Namzaric on the horizon. Report
Animal Health News
> Iowa biotech firm set to begin testing vaccine against deadly avian flu. Item
> Phibro records strong sales growth despite industry shift from antibiotics. Report
> ImmuCell enjoys spoils of success as demand for calf protector exceeds supply. More
> Jaguar's delayed and downsized IPO garners muted reception on Wall Street. Story
> FDA warns Lilly to stop marketing antibiotic for weight gain in pigs. Article
Biotech IT News
> GenomeDx shares 7 years of cancer testing data with medical center. Item
> Venter's HLI scoops samples from Cleveland Clinic as data-generating drive continues. More
> Allen Institute advances brain-mapping ambitions with cell-type database. Story
> Regeneron lobbying for its database to be the linchpin of Obama's Precision Medicine program. Article
> AstraZeneca dives into genetics of 80,000 samples in search of CV, diabetes insights. Report